Healthcare [ 12/13 ] | Drug Manufacturers - Specialty & Generic [ 84/164 ]
NASDAQ | Common Stock
Viatris Inc. operates as a healthcare company worldwide.
The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names.
The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 0.67 Decreased by -12.99% | 0.67 |
| Mar 27, 24 | 0.62 Decreased by -7.46% | 0.65 Decreased by -4.62% |
| Nov 7, 23 | 0.79 Decreased by -9.20% | 0.74 Increased by +6.76% |
| Aug 7, 23 | 0.75 Decreased by -14.77% | 0.71 Increased by +5.63% |
| May 8, 23 | 0.77 Decreased by -17.20% | 0.69 Increased by +11.59% |
| Feb 27, 23 | 0.67 Decreased by -16.25% | 0.72 Decreased by -6.94% |
| Nov 7, 22 | 0.87 Decreased by -12.12% | 0.84 Increased by +3.57% |
| Aug 8, 22 | 0.88 Decreased by -10.20% | 0.83 Increased by +6.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 3.82 B Increased by +2.56% | -765.60 M Decreased by -440.72% | Decreased by -20.02% Decreased by -432.22% |
| Dec 31, 23 | 3.82 B Decreased by -1.33% | -765.60 M Decreased by -175.71% | Decreased by -20.02% Decreased by -176.73% |
| Sep 30, 23 | 3.94 B Decreased by -3.34% | 331.60 M Decreased by -6.41% | Increased by +8.41% Decreased by -3.17% |
| Jun 30, 23 | 3.92 B Decreased by -4.81% | 264.00 M Decreased by -15.90% | Increased by +6.74% Decreased by -11.64% |
| Mar 31, 23 | 3.73 B Decreased by -11.04% | 224.70 M Decreased by -43.71% | Increased by +6.03% Decreased by -36.73% |
| Dec 31, 22 | 3.88 B Decreased by -10.72% | 1.01 B Increased by +483.32% | Increased by +26.09% Increased by +529.37% |
| Sep 30, 22 | 4.08 B Decreased by -10.10% | 354.30 M Increased by +13.74% | Increased by +8.69% Increased by +26.52% |
| Jun 30, 22 | 4.12 B Decreased by -10.07% | 313.90 M Increased by +212.43% | Increased by +7.62% Increased by +225.02% |